Menoflavon Product Update

RNS Number:9652A
BioProgress PLC
27 July 2007


For Immediate Release                                              27 July 2007

                BioProgress plc ('BioProgress' or the 'Company')

                          MenoflavonTM Product Update

London, UK, 27 July 2007: BioProgress plc (AIM: BPRG), the speciality pharma and
healthcare company, has today announced that Melbrosin will be sponsoring
lectures at the First International Congress of Breast Development, Functions
and Diseases in Turin, Italy on 28-30 September 2007 and promoting MenoflavonTM,
its natural product for menopausal symptoms, to 800 delegates. The MenoflavonTM
brand will also be launched in France to coincide with the Congress.

The lectures that highlight the use of MenoflavonTM will be given by two leading
key opinion leaders in the field of female health, Professor Martin Imhof from
the Medical University of Vienna, Austria and Dr Tommaso Simoncini from the
University of Pisa, Italy.

The lectures will be part of a session on Red clover isoflavones and breast.
Prof. M. Imhof will present a lecture on "The impact of isoflavones on breast"
and Dr. T. Simoncini will discuss "Estrogens, phytoestrogens and the
postmenopausal woman: impact on the cardiovascular system and on the breast".

Isoflavones derived from red clover, the main constituent of MenoflavonTM, in
addition to being an alternative to hormone replacement therapy, potentially
have beneficial cardiovascular actions, along with estrogen antagonistic actions
on breast cancer cells which will be discussed in this lecture, along with the
implications for the care of postmenopausal women.

MenoflavonTM is a strategic growth product of Melbrosin and is currently being
marketed in Germany, Austria and Italy. Since its launch in 2001, MenoflavonTM
has sold over 2.5 million units and is one of the leading red clover products
worldwide. It is currently available in 20 markets and it is anticipated to
launch in H2 2007 into six additional South American countries. The product
sales are currently growing at 14-30% per annum. The non-prescription menopausal
product market is estimated to be in excess of Euro200m in the top six countries in
Europe, with Germany accounting for Euro75m, France Euro57m and Italy Euro23m.

From the cash raised at the time of the Melbrosin acquisition, MenoflavonTM will
be launched in France to coincide with the presentations. It is anticipated that
the range of products available will be extended by utilising BioProgress' X-Gel
technology. It is expected that other territory launches will occur throughout
the remainder of 2007.


Richard Trevillion, Chief Executive Officer, BioProgress, said:

"This is an important step in our development as a speciality pharmaceutical
company. This launch demonstrates the fast organic growth of our core brands.
With the rollout of the brand to multiple territories over the coming months, we
are pleased that our integration strategy is on track and poised for strong
growth."


Steve Martin, Chief Development Officer, BioProgress, said:

"BioProgress is pleased that we are able to promote MenoflavonTM to the
established medical and pharmaceutical industries. The potential benefits of
MenoflavonTM are only just being understood and with potentially wider benefits
against the traditional hormone replacement market, MenoflavonTM is able to
offer real choice in alternative therapy. The use of such international meetings
is a core strategy of the business going forward as it seeks to expand, and
validate, the uses and indications of products and technologies that have been
acquired or are under development. "


Klaus Kuhne, Joint Managing Director, Melbrosin, said:

"We have a strong science behind our core brands, with MenoflavonTM being no
exception. The superior nature of the product compared to its peers has allowed
the brand to enjoy healthy growth potential. We have two internationally
recognised key opinion leaders who have conducted research into MenoflavonTM. We
are excited that we are able to expand our promotional efforts and increase the
distribution as a direct result of working with and being part of BioProgress."



For further information:


BioProgress Plc                                + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                        + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court





About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, the company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGELTM
polymer technology, replacing the need to use animal-derived gelatine in
pharmaceutical and healthcare products. For further information please go to
www.bioprogress.com



Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.










                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCRFMRTMMJTBTR
Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024